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Abstract
Background: Stavudine is an effective and inexpensive antiretroviral drug, but no longer recommended by WHO for first-
line antiretroviral regimens in resource-limited settings due to toxicity concerns. Because of the high cost of alternative
drugs, it has not been feasible to replace stavudine in most adults in the Malawi ART programme. We aimed to provide
policy makers with a detailed picture of stavudine toxicities in Malawians on longer-term ART, in order to facilitate
prioritization of stavudine replacement among other measures to improve the quality of ART programmes.
Methods: Prospective cohort of Malawian adults who had just completed one year of stavudine containing ART in an urban
clinic, studying peripheral neuropathy, lipodystrophy, diabetes mellitus, high lactate syndromes, pancreatitis and
dyslipidemia during 12 months follow up. Stavudine dosage was 30 mg irrespective of weight. Cox regression was used
to determine associations with incident toxicities.
Results: 253 patients were enrolled, median age 36 years, 62.5% females. Prevalence rates (95%-confidence interval) of
toxicities after one year on stavudine were: peripheral neuropathy 21.3% (16.5–26.9), lipodystrophy 14.7% (2.4–8.1), high
lactate syndromes 0.0% (0–1.4), diabetes mellitus 0.8% (0–2.8), pancreatitis 0.0% (0–1.5). Incidence rates per 100 person-
years (95%-confidence interval) during the second year on stavudine were: peripheral neuropathy 19.8 (14.3–26.6),
lipodystrophy 11.4 (7.5–16.3), high lactate syndromes 2.1 (0.7–4.9), diabetes mellitus 0.4 (0.0–1.4), pancreatitis 0.0 (0.0–0.2).
Prevalence of hypercholesterolemia and hypertriglyceridemia increased from 12.1% to 21.1% and from 29.5% to 37.6%
respectively between 12 and 24 months. 5.5% stopped stavudine, 1.3% died and 4.0% defaulted during follow up. Higher
age was an independent risk factor for incident peripheral neuropathy and lipodystrophy.
Conclusion: Stavudine associated toxicities continued to accumulate during the second year of ART, especially peripheral
neuropathy and lipodystrophy and more so at increasing age. Our findings support investments for replacing stavudine in
first-line regimens in sub-Saharan Africa.
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Introduction
In 2004 Malawi successfully embarked on an antiretroviral
therapy (ART) scale-up programme with a public health
approach. Important characteristics of this programme are free
treatment, standardized drug regimens, simplified and mainly
clinical monitoring and promotion of decentralized clinical care
[1,2]. At the end of 2011 over 250,000 patients were receiving
ART. Although a new first-line regimen without stavudine was
introduced in 2011for certain priority groups, around 90% of
patients still use the standard generic combination of stavudine,
lamivudine and nevirapine [3].
Stavudine is inexpensive, potent, has a relatively high barrier to
resistance and is available in a generic combination tablet.
Experience in several African countries has shown that during
the first stages of treatment stavudine can be used without
laboratory monitoring for side effects. However, stavudine is no
longer recommended in first-line ART regimens in affluent
countries due to its unfavorable toxicity profile. Several studies
have provided insight into the occurrence of stavudine related side
effects in patients from sub-Saharan Africa. Peripheral neuropathy
is one of the most common toxicities with prevalence rates that
varied from 20 to 34% after 1 to 3 years in Uganda, South Africa
and Kenya [4,5]. Two studies showed a high prevalence of
lipodystrophy in adult Rwandans on stavudine [6,7]. High lactate
syndromes are relatively rare, but appear to occur more frequently
than in affluent countries and lactic acidosis carries a very high
mortality [8]. Pancreatitis is another serious side effect associated
with stavudine, which appeared to be uncommon in Ugandans
[4], although cases may have been missed due to the retrospective
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design, the non-specific presentation and lack of diagnostic tests.
Dyslipidemia, glucose intolerance and diabetes mellitus are
common in western patients on ART, probably due to HIV
infection, antiretroviral drugs as well as traditional risk factors.
Because monitoring of lipid and glucose levels during ART is
rarely feasible in sub-Saharan Africa, data from the region are
sparse.
WHO has recently recommended that stavudine should be
replaced in standard first-line ART regimens in resource limited
settings, preferably with tenofovir [9]. In Malawi, this is being
implemented for children, pregnant and breast feeding women
and patients receiving TB treatment but replacing stavudine for all
adult patients is currently unaffordable. Indeed, due to the large
number of patients involved, the budgetary demands of introduc-
ing more expensive alternatives to stavudine are considerable [10]
and may compete with other priorities to improve ART
programmes such as extending ART eligibility and viral load
monitoring for ART failure.
To assist policy makers in their decisions about the replacement
of stavudine in the first-line regimen we have prospectively
monitored the full burden of stavudine toxicities in a cohort of
patients who had just completed one year of treatment in Blantyre,
Malawi. We have also identified the risk factors for these stavudine
toxicities.
Methods
Study site and subjects
The study took place at the ART clinic of Queen Elizabeth
Central Hospital, in Blantyre, the commercial capital of the
Southern region of Malawi. The clinic was established in 2000,
started providing ART free of charge in 2004, and currently cares
for around 9,000 patients on ART. We enrolled consecutive
patients aged 15 years and above, living in the hospital catchment
area, who had started ART at the clinic and had just completed
one year of stavudine containing treatment. They were seen for
routine ART care and study procedures at baseline (i.e. 12 months
after ART initiation) and 3, 6, 9 and 12 months later. Patients
were encouraged to visit the clinic in case of any intercurrent
illness. We did not trace participants actively in the community if
they did not attend for follow up visits.
Data collection and diagnostic procedures
At enrolment demographic information and details of the ART
history were recorded. A standard proforma for symptoms and
physical examination was used. We diagnosed peripheral neurop-
athy on the basis of characteristic symptoms that had started after
the initiation of ART. Due to lack of sophisticated imaging
techniques to diagnose lipodystrophy, we used the Lipodystrophy
Case Definition Study-based Questionnaire [11] at baseline and
after six and 12 months. This instrument has been validated in
African settings [7] and is a combination of patient self-assessment
and inspection by the clinician of seven body areas (face, neck,
chest, abdomen, arms, legs and buttocks). Body shape changes
were scored as minimal, moderate or much. Fat loss and gain were
distinguished. To diagnose pancreatitis, we investigated all new
episodes of abdominal pain with an amylase serum level and
abdominal ultrasonography. Lactate was measured at each visit
with the hand-held Lactate ProH (Arkray Europe B.V., Amstelv-
een, the Netherlands) at the point-of-care. Patients were rested and
were checked for dehydration before sampling. Strongly elevated
values were confirmed with a repeat test plus determination of an
anion gap and venous CO2 level. We diagnosed the following high
lactate syndromes: severe hyperlactatemia if lactate was repeatedly
.5.0 mmol/L (reference range ,2.2 mmol/L) without symp-
toms; symptomatic hyperlactatemia if lactate was repeatedly
.5.0 mmol/L and symptoms associated with lactic acidosis were
present and lactic acidosis if there were also manifestations of
metabolic acidosis (acidotic breathing and/or reduced venous
CO2 and an increased anion gap). A diagnosis of diabetes mellitus
was based on WHO criteria [12]: if a random or fasting blood
glucose was repeatedly higher than 200 mg/dL or 126 mg/dL
respectively. A serum lipid spectrum was determined at enrolment
and after 12 months (non-fasting) with the Beckman Coulter CX5
Pro (Beckman Coulter, Halfway House, RSA). Study participants
experiencing peripheral neuropathy, lipodystrophy, a high lactate
syndrome, pancreatitis and/or diabetes were labeled as ‘‘any
stavudine toxicity’’.
To obtain an overview of stavudine toxicities in the first year on
ART, we retrospectively studied patient records of all adults who
started ART at Queen Elizabeth Central Hospital during the same
episode as the study participants but were not enrolled into the
cohort. We collected patient characteristics at the start of ART,
standardized ART outcomes and information about toxicity
events leading to replacement of stavudine during the first year
on ART.
Statistics
Data were double entered into a secure Microsoft Access SQL
database. For statistical analyses Stata for windows software
(version SE/11; 4905; Stata corp; College Station, Texas 77845
USA) was used. Patient characteristics were compared with Chi-
squared and t-tests. The prevalence rates at enrolment and
incidence rates during follow-up, of high lactate syndromes,
lipodystrophy, peripheral neuropathy, pancreatitis, dyslipidemia
and diabetes mellitus were expressed with 95% confidence
intervals. The probability of experiencing each of the toxicities
at specific follow-up time points were estimated using Kaplan-
Meier curves; between group comparisons were performed using
log rank tests. Risk factors for incident toxicities were assessed
using Cox proportional hazards regression models which included
age, sex, body mass index (BMI), WHO stages, previous diagnosis
of tuberculosis, estimated creatinine clearance, smoking and
alcohol use. Diagnostic checks to assess the appropriateness of
the proportional hazard assumptions were done using Schoenfeld
residuals. A paired t-test was used to assess change in serum lipids
levels between month12 and month 24 on ART. All tests were 2-
sided and were tested at 5% level of significance.
Ethical considerations
The study was approved by the College of Medicine Research
and Ethics Committee (study number P.01/09/719) and written
informed consent was obtained from all patients.
Results
Enrolment process
From May through September 2009, we consecutively enrolled
253 patients who had just completed one year of ART into the
prospective cohort study. These study participants originated from
544 adults who had started the standard first-line ART regimen
(stavudine-lamivudine-nevirapine) at QECH from May through
September 2008. The mortality, default and transfer-out rates for
patients in the first year of routine ART care were 3.9%, 18.4%
and 8.8% respectively. Figure 1 shows attrition during the first year
on ART and other reasons for not enrolling patients. Out of the
291 patients who were not enrolled in our prospective cohort,
adequate information was available in the routine system of 190.
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When we compared these 190 patients to the study participants
(n = 253), we found that mean age (36.3 vs. 36.6 years; p = 0.72),
prevalence of female gender (58.5 vs. 62.5%; p = 0.38) and median
CD4 count at ART initiation (141.0 vs. 141.0 cells/micro-liter;
p = 0.69) were similar. However, study participants were less
frequently in WHO stage 3 or 4 (41.9 vs. 60.3%; p,0.001).
Patient characteristics
Patient characteristics in table 1 show that a considerable
percentage of study participants had had progressive clinical
disease and/or advanced immune suppression when they started
ART. The mean age of females was lower, fewer females had
received tuberculosis treatment, fewer reported current alcohol
Figure 1. Study diagram.
doi:10.1371/journal.pone.0042029.g001
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consumption and they had a higher estimated creatinine clearance
compared to males.
Standard ART outcomes
During their second year on ART, three patients died (1.3%;
95%-CI 0.2–30.0), ten defaulted (4.0%; 95%-CI 2.0–6.6), three
transferred to another clinic (1.3%; 95%-CI 0.2–30.0), one
withdrew from the study and none stopped ART during follow
up (figure 1). No patient started a second-line regimen due to ART
failure.
Stavudine related toxicities
At enrolment, i.e. after one year on stavudine containing ART,
side effects were common, in particular peripheral neuropathy and
lipodystrophy. Incidence rates of peripheral neuropathy and
lipodystrophy in the second year on ART were high, but there
were few new high lactate syndromes and diabetes diagnoses and
no case of pancreatitis (table 2). Time to first stavudine toxicity in
patients free from side effects at enrolment is indicated in figure 2,
showing that the time to first toxicity was significantly shorter in
those aged younger than 40 years (log-rank p,0.0001). There was
good agreement between patients and investigators in the
assessment of the presence of lipodystrophy; discrepancies
occurred only in 16 out of 732 assessments (2.2%). Where
discrepancies occurred, six times patients noted changes that were
not observed by investigators and ten times vice versa. Of the
patients who had lipodystrophy, 27.3% had lipo-hypertrophy,
39.4% had lipo-atrophy and 33.3% had both. The self-reported
Table 1. Patient characteristics.
Characteristic Females Males Total P-value
N 158 (62.5) 95 (37.5) 253
Median age (IQR), years 33 (29–40) 38 (34–46) 36 (31–43) 0.001
Median BMI (IQR), kg/m2 23.5 (20.9–26.1) 22.4 (21.2–24.6) 23.1 (21.2–25.5) 0.076
BMI categories
underweight (,18.5 kg/m2) 7 (4.4) 3 (3.2) 10 (4.0) 0.073
normal (18,5–25 kg/m2) 98 (62.0) 72 (75.8) 170 (67.0)
overweight (.25 kg/m2) 43 (27.0) 19 (20.0) 62 (25.0)
missing 10 (6.0) 1 (1.0) 11 (4.0)
Median CD4 at start ART (cells/mL) 155 114 141 0.28
0–199 101 (67.8) 65 (74.7) 166 (65.6) 0.524
200–349 43 (28.9) 20 (23.0) 63 (24.9)
$350 5 (3.4) 2 (2.3) 7 (2.8)
missing 9 (5.7) 8 (8.4) 17 (6.7)
WHO stage at start ART
I 39 (24.7) 18 (18.9) 57 (22.5) 0.119
II 61 (38.6) 29 (30.5) 90 (35.6)
III 42 (26.6) 39 (41.1) 81 (32.0)
IV 16 (10.1) 9 (9.5) 25 (10.0)
Current smoker 0 0 0
Current alcohol user 1 (0.6) 6 (6.3) 7 (2.8) 0.008
Previous TB treatment 33 (20.9) 33 (34.7) 66 (26.1) 0.015
Previous KS diagnosis 3 (1.8) 3 (1.8) 6 (2.3) 0.524
Median eCC (IQR), ml/min 90.4 (74.5–104.7) 71.9 (63.5–82.6) 82.1 (70.1–98.7) ,0.001
eCC categories
$90 81 (52.3) 39 (41.1) 120 (49.9) 0.112
89–60 63 (39.9) 50 (52.6) 113 (44.7)
59–30 8 (5.2) 2 (2.1) 10 (3.9)
,30 4 (2.5) 4 (4.2) 8 (3.1)
missing 4 (2.5) 4 (4.2) 4 (4.2)
On cotrimoxazole prophylaxis 139 (88.1) 85 (89.5) 224 (88.5) 0.288
ART regimen
Stavudine/lamivudine/nevirapine 145 (91.8) 89 (93.7) 234 (92.5) 0.576
Stavudine/lamivudine/other 13 (8.2) 6 (6.3) 19 (7.5)
All characteristics are expressed as n (%) and are measured at enrolment, unless otherwise indicated.
All characteristics are at enrolment into the study (after one year on ART), except WHO stage and CD4 count as indicated.
IQR, inter-quartile range; BMI, body mass index; ART, antiretroviral therapy; WHO, world health organization; TB, tuberculosis; KS, Kaposi’s sarcoma; eCC, estimated
creatinine clearance (Cockroft-Gault method).
doi:10.1371/journal.pone.0042029.t001
Stavudine Toxicity Malawi
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e42029
severity of lipodystrophy was as follows: 10.3% severe, 37.9%
moderate and 51.7% mild, and 96.4% said it had no impact on
adherence.
Elevated levels of total cholesterol and triglycerides were
common but levels were generally only mildly raised. Dyslipidemia
appeared to progress over time, reflected in a significant increase
in the mean total cholesterol/HDL-cholesterol ratio (table 3).
Fourteen patients (5.5%) changed from stavudine to zidovudine
during follow up due to severe toxicity and in all except one,
multiple side effects were present.
Risk factors for common stavudine associated toxicities
Higher age was significantly associated with incident peripheral
neuropathy, lipodystrophy and ‘‘any toxicity’’ in uni- and
multivariate Cox regression analyses. Being in WHO clinical
stage 3 or 4 (versus being in stage 1 or 2) at ART initiation was also
independently associated with incident lipodystrophy (table 4).
Discussion
We demonstrate a high prevalence of stavudine associated
toxicities in a cohort of Malawian adults who completed the first
year on ART and a high incidence of toxicities as they continued a
stavudine based regimen. There was frequent occurrence of
peripheral neuropathy and lipodystrophy, while high lactate
syndromes and diabetes mellitus were rare and no pancreatitis
was observed. Considerable toxicity related attrition from the
standard regimen occurred, 10.5% replacing stavudine in the first
year and 5.5% in the second.
Although the use of stavudine is declining in sub-Sahara Africa,
this potent antiretroviral drug is still used by many adults in the
region [13]. Good results have been achieved with stavudine based
generic formulations, evidenced by low rates of treatment failure
and switching to second-line regimens in observational studies
from Mozambique [14], Cameroon [15], and Malawi [16]. In one
of the few randomized controlled trials of ART regimens from
Africa, a backbone of stavudine/lamivudine performed better than
zidovudine/didanosine in terms of virological suppression and
immune reconstitution, although toxicity was more severe [17].
As scale-up of ART progressed in sub-Saharan Africa, a
number of cohort studies have highlighted the toxicity concerns of
stavudine. Peripheral neuropathy (36%), but not pancreatitis
(0.3%) and lactic acidosis (0.1%) were common in adult Ugandans
starting stavudine based ART in a home-based care project in
2003–4 and being followed for a median of 11 months. Age $35
years and tuberculosis treatment were identified as risk factors for
peripheral neuropathy [4]. A study from Kigali, Rwanda followed
patients started on stavudine/lamivudine/nevirapine from 2003–
7. Toxicity severe enough to replace stavudine was observed in
18.8%, mainly due to peripheral neuropathy (8.0%), lactic
acidosis/symptomatic hyperlactatemia (3.1%) and lipodystrophy
(7.2%). In this population, higher age and more advanced clinical
stage were risk factors for peripheral neuropathy, female gender
for lipodystrophy and higher weight and female gender for lactic
acidosis/symptomatic hyperlactatemia [18]. In a large cohort from
Johannesburg, South Africa, observed during 2004–8, moderate
rates of peripheral neuropathy (17.1%) and lipodystrophy (7.4%)
were found among those on stavudine. A large proportion (8.2%)
experienced lactic acidosis/symptomatic hyperlactatemia. Women
were at higher risk of all toxicities than men, except for peripheral
neuropathy [5]. Although retention in care and virological control
were good, substitution of stavudine was extremely common,
especially among women [19].The same research group had
earlier shown that stavudine substitutions were increased when
ART was started with ongoing and concurrent TB treatment, but
not in incident TB cases on established ART [20]. Female gender
was also a major predictor of stavudine substitutions due to side
effects in a cohort of adult Ugandans in Kampala [21].
These studies of stavudine toxicity are all limited by the fact that
patients over 60 kg were exposed to a dosage of 40 mg per day.
Since 2007 WHO has recommended dosing 30 mg of stavudine
daily, irrespective of weight, as this is equally effective with a
potentially lower rate of side effects [22]. Our study, in which
47.4% participants weighed .60 kg, shows that despite universal
30 mg dosing, stavudine associated toxicities are very common.
Figure 2. Time to first stavudine toxicity (peripheral neurop-
athy, lipodystrophy, high lactate syndrome, pancreatitis or
diabetes) in patients starting the second year of stavudine
containing ART without any of these toxicities.
doi:10.1371/journal.pone.0042029.g002
Table 2. Prevalence rates at enrolment and incidence rates
during 12 months of follow up of stavudine associated
toxicities in 253 Malawian adults.
Toxicity Prevalence Rate* Incidence Rate
PR (%) 95%-CI IR (/100 py) 95%-CI
Peripheral neuropathy 21.3 16.5–26.9 19.8 14.3–26.6
Lipodystrophy 14.7 2.4–8.1 11.4 7.5–16.3
Pancreatitis 0 0–1.5 0 0.0–0.2
Diabetes mellitus 0.8 0–2.8 0.4 0.0–1.4
High lactate syndrome{ 0 0–1.4 2.1 0.7–4.9
Increased TC
(.200 mg/dL)
11.9 8.1–16.4 9.9 7.9–13.3
Increased TG
(.110 mg/dL)
5.5 3.1–9.1 13.9 9.2–16.7
Any toxicity" 22.9 17.8–28.6 26.7 20.1–34.8
*Prevalence at enrolment i.e. after one year of stavudine containing ART.
"One or more of peripheral neuropathy, lipodystrophy, pancreatitis,
hyperlactate syndrome, diabetes mellitus.
{severe hyperlactatemia, symptomatic hyperlactatemia and lactic acidosis, as
defined in methods paragraph.
IR, incidence rate; PR, prevalence rate; CI, confidence interval; py, person-years;
TC, total cholesterol serum level; TG, triglyceride serum level.
doi:10.1371/journal.pone.0042029.t002
Stavudine Toxicity Malawi
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e42029
The pattern of stavudine toxicities we found was largely
comparable to the sub-Saharan studies described above. Our rate
of lactic acidosis and symptomatic hyperlactatemia was somewhat
lower than in some studies [5,6] possibly because the patients we
had enrolled had a relatively low mean BMI at the start of ART
and we dosed 30 mg to heavier patients. We did not observe any
cases of pancreatitis despite evaluating all suspected episodes.
Others also found very few pancreatitis cases and because the
epidemiology of pancreatitis in African populations is not well-
known, it remains uncertain whether HIV and/or stavudine
actually are risk factors. Dyslipidemia has been studied infre-
quently in ART patients from sub-Saharan Africa. Hypertriglyc-
eridemia and hypercholesterolemia were present in 9% and 14%
of adult Rwandans with lipodystrophy on mainly stavudine
containing ART for at least 6 months. No hyperlipidemia was
identified in patients without lipodystrophy [8]. Lipid profiles of
rural Ugandans, studied at the start of stavudine containing ART
and after 12 and 24 months, showed that mean total-, LDL- and
HDL-cholesterol levels all increased over time, while mean
triglyceride levels initially declined at 12 months, only to return
to the baseline value after 24 months [23]. Although we did not
have the benefit of pre-ART lipid values, over the course of the
second year on ART we found trends of an increasing mean total
cholesterol level and a decreasing mean HDL-cholesterol level, as
well as a significantly increased mean total- to HDL-cholesterol
ratio. Our data therefore suggest gradual atherogenic lipid
changes with ongoing stavudine based ART. Further studies with
longer follow up need to clarify whether stavudine induced lipid
changes are associated with actual increased risk of cardiovascular
disease.
We found that higher age was a risk factor for peripheral
neuropathy as was the case in other studies [4,17] and for
lipodystrophy and ‘‘any stavudine toxicity’’. This suggests that
older patients have to be considered as a priority group qualifying
for a non-stavudine containing standard first-line regimen, as is
currently the case in Malawi with children, breastfeeding and
pregnant women and TB patients [24].
Strengths of our study are that we comprehensively describe the
full array of stavudine associated toxicities and that we had low
losses to follow up. Limitations also need to be considered. We
enrolled patients who had remained on stavudine containing ART
in the clinic one year after starting treatment. For a complete
picture of stavudine toxicities in the first year, events in all patients
who started stavudine/lamivudine/nevirapine at the same time as
Table 3. Analysis of changes in serum lipid levels over time.
Lipids n month 12* month 24 mean change 95% CI change p-value
Mean TC (mg/dL) 209 159.5 163.9 4.4 20.6–9.4 0.083
% elevated TC (.200 mg/dL) 12.1 21.1 0.1104
Mean LDL-c (mg/dL) 131 86.4 88.1 1.7 22.5–6 0.42
% elevated LDL-c (.130 mg/dL) 5.3 7.6 0.4955
Mean HDL-c (mg/dL) 183 50.5 48.3 22.2 24.5–0.1 0.06
% decreased HDL-c (,40 mg/dL) 27.3 31.6 0.908
Mean TG (mg/dL) 202 96.5 103.3 6.6 21.4–14.8 0.106
% elevated TG (.110 mg/dL) 29.5 37.6 0.005
Mean TC/HDL-c ratio 183 3.3 3.6 0.3 0.2–0.4 ,0.001
% elevated TC/HDL-c ratio (.5) 5.5 9.8 0.121
TC, total cholesterol; LDL-c, low density lipoprotein cholesterol; HDL-c, high density lipoprotein cholesterol; TG, triglyceride.
*At the time of enrolment into the study, after 12 months of stavudine containing ART.
doi:10.1371/journal.pone.0042029.t003
Table 4. Cox regression models of variables associated with stavudine associated side effects.
Variable Peripheral Neuropathy Lipodystrophy Any toxicity
"
HR (95%-CI) aHR (95%-CI) HR (95%-CI) aHR (95%-CI) HR (95%-CI) aHR (95%-CI)
Male gender 1.26 (0.64–2.48) 1.67 (0.59–4.72) 0.73 (0.23–1.41) 0.73 (0.23–2.40) 1.05 (0.61–1.81) 1.08 (0.48–2.42)
Age (years) 1.04 (1.02–1.08) 1.04 (1.00–1.08) 1.06 (1.03–1.11) 1.08 (1.04–1.13) 1.05 (1.02–1.08) 1.05 (1.02–1.08)
BMI (kg/m2) 1.05 (0.99–1.14) 1.07 (0.97–1.18) 0.98 (0.87–1.10) 0.97 (0.84–1.12) 1.07 (1.00–1.15) 1.08 (0.99–1.17)
WHO stage* 1.36 (0.70–2.64) 1.68 (0.82–3.44) 0.52 (0.22–1.26) 0.37 (0.14–0.98) 0.95 (0.55–1.65) 0.96 (0.53–1.74)
Alcohol use 0.74 (0.10–5.74) 1.00 (0.13–7.85) 0.46 (0.06–3.31) 0.63 (0.08–4.79)
TB diagnosis{ 0.65 (0.27–1.58) 0.61 (0.24–1.58) 0.92 (0.48–1.75) 1.15 (0.56–2.34)
eCC (mL/min) 1.00 (0.99–1.02) 0.99 (0.96–1.01) 0.98 (0.96–1.00) 0.99 (0.96–1.02) 1.00 (0.99–1.01) 0.99 (0.96–1.01)
"One or more of peripheral neuropathy, lipodystrophy, pancreatitis, high lactate syndrome, diabetes mellitus.
HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval, BMI, body mass index; WHO, world health organization; TB, tuberculosis;
eCC, estimate creatinine clearance.
*WHO stage refers to being in WHO clinic stage 3 or 4 vs. being in stage 1 or 2 at the start of ART. Significant associations are indicated in bold font.
{TB diagnosis refers to previous and current diagnosis.
doi:10.1371/journal.pone.0042029.t004
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our participants and were not enrolled needed to be regarded.
However description of events in these patients depended on
retrospective analysis of routine data from patient records and the
electronic database of the clinic. This may have resulted in a less
complete and accurate overview of stavudine side effects in the first
year on ART. Although we have assumed that the described
adverse effects were toxicities of stavudine, it cannot be excluded
that in some cases other factors were important, such as
lamivudine toxicity and impact of the virus itself. Comparison of
toxicities in patients who are not on stavudine are not available
from Malawi, because all patients have started the same first-line
regimen since the commencement of the scale up programme.
Only very recently has a new first-line regimen, consisting of
tenofovir, lamivudine and efavirenz been introduced for certain
priority groups. We did not use some objective measures (waist-to-
hip ration) and methods (DEXA scanning) for the determination
of lipodystrophy. Our study was done in an urban rather than a
rural clinic which must be considered when extrapolating to other
settings.
In times of economic austerity, it is crucial for donor funded
programmes to continue using standardized, affordable first-line
regimens, so as to avoid treatment discontinuations due to drug
stock outs, since this is associated with interruption of care and
with death [25]. In a computer model of HIV treatment in RSA,
stavudine/lamivudine/nevirapine was the least cost-effective of
five regimens considered (despite the lower drug price) and
tenofovir/lamivudine/efavirenz the most cost-effective [10].
However considerable initial investments for an alternative to
stavudine are needed. This appears justifiable given the high rates
of toxicity we and others recorded. Stavudine toxicities obviously
cause direct harm to patients, also have the potential to increase
the rate of cardio- and cerebro-vascular disease, and increasingly
attract national media attention, particularly in relation to
lipodystrophy [26], together affecting the reputation of ART in
general. Our data provide further compelling evidence for the
donor community and national governments to prioritize the
replacement of stavudine in the standard first-line regimen for
adults in sub-Saharan Africa.
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